These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 26023014)

  • 21. The clinical management of hyperphosphatemia.
    Ritz E
    J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK; Choi HY; Shin SK; Lee HY
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.
    Yamada S; Yoshida H; Taniguchi M; Tanaka S; Eriguchi M; Nakano T; Tsuruya K; Kitazono T
    Intern Med; 2012; 51(16):2097-104. PubMed ID: 22892485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
    Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
    J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lanthanum carbonate: safety data after 10 years.
    Hutchison AJ; Wilson RJ; Garafola S; Copley JB
    Nephrology (Carlton); 2016 Dec; 21(12):987-994. PubMed ID: 27479781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
    Sprague SM; Abboud H; Qiu P; Dauphin M; Zhang P; Finn W
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):178-85. PubMed ID: 19056618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS; Finn WF;
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.
    Vegter S; Tolley K; Keith MS; Postma MJ
    Value Health; 2011; 14(6):852-8. PubMed ID: 21914505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
    Altmann P; Barnett ME; Finn WF;
    Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L; Liu A; Xu G
    Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphate binders in CKD: chalking out the differences.
    Rees L; Shroff RC
    Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    St Peter WL; Wazny LD; Weinhandl ED
    Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
    Floege J
    J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
    Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
    Goto S; Komaba H; Moriwaki K; Fujimori A; Shibuya K; Nishioka M; Kim JI; Yoshiya K; Shin J; Hasegawa H; Taniguchi M; Fujii H; Nishi S; Kamae I; Fukagawa M
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1375-84. PubMed ID: 21551021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
    Ando R; Kimura H; Sato H; Iwamoto S; Yoshizaki Y; Chida Y; Ishida Y; Takayama M; Yamada K; Tachibana K; Ohtsuka M; Kikuchi K; Inoue A
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():2-8. PubMed ID: 23586506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.